https://orcid.org/0000-0002-6988-9421
References
- Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502.
- Mahar AL, Compton C, Halabi S, et al. Personalizing prognosis in colorectal cancer: a systematic review of the quality and nature of clinical prognostic tools for survival outcomes. J Surg Oncol. 2017;116(8):969–982.
- Ye L, Zhang T, Kang Z, et al. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front Immunol. 2019;10:2368.
- Allison KE, Coomber BL, Bridle BW. Metabolic reprogramming in the tumour micro environment: a hallmark shared by cancer cells and T lymphocytes. Immunology. 2017;152(2):175–184.
- Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–118.
- Francini E, Ou FS, Lazzi S, et al. The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II Colon cancer according to use of adjuvant chemotherapy: a large single-institution cohort study. Transl Oncol. 2021;14(2):100973.
- Glaire MA, Domingo E, Sveen A, et al. Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. Br J Cancer. 2019;121(6):474–482.
- Fletcher R, Wang YJ, Schoen RE, et al. Colorectal cancer prevention: immune modulation taking the stage. Biochim Biophys Acta Rev Cancer. 2018;1869(2):138–148.
- Marisa L, Svrcek M, Collura A, et al. The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of Colon tumors. J Natl Cancer Inst. 2018;110(1):68–77.
- Hu X, Li YQ, Ma XJ, et al. A risk signature with inflammatory and T immune cells infiltration in colorectal cancer predicting distant metastases and efficiency of chemotherapy. Front Oncol. 2019;9:704.
- Hu X, Li YQ, Li QG, et al. ITGAE defines CD8+ tumor-infiltrating lymphocytes predicting a better prognostic survival in colorectal cancer. EBioMedicine. 2018;35:178–188.
- Kuwahara T, Hazama S, Suzuki N, et al. Intratumoural-infiltrating CD4+ and FOXP3+ T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. Br J Cancer. 2019;121(8):659–665.
- Zhang L, Yu X, Zheng L, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564(7735):268–272.
- Xu F, Li S, Zhang J, et al. Cancer stemness, immune cells, and epithelial-mesenchymal transition cooperatively predict prognosis in colorectal carcinoma. Clin Colorectal Cancer. 2018;17(3):e579–e592.
- Saito T, Nishikawa H, Wada H, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22(6):679–684.
- Kong JC, Guerra GR, Pham T, et al. Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 2019;62(4):498–508.
- Doulabi H, Rastin M, Shabahangh H, et al. Analysis of Th22, Th17 and CD4 + cells co-producing IL-17/IL-22 at different stages of human colon cancer. Biomed Pharmacother. 2018;103:1101–1106.
- Dylag-Trojanowska K, Rogala J, Pach R, et al. T regulatory CD4 + CD25 + FoxP3+ lymphocytes in the peripheral blood of left- sided colorectal cancer patients. Medicina (Kaunas). 2019;55(6):307.
- Chen T, Li Q, Zhang X, et al. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection. Hum Pathol. 2018;79:93–101.